Comments on the FDA’s Proposal to Exclude 19 Bulk Drug Substances From the 503B Bulks List for Pharmacy Compounding by Outsourced Facilities

View as PDF

Public Citizen strongly supports the Food and Drug Administration’s (FDA’s) proposal to exclude 19 bulk drug substances from the list of bulk drug substances for which there is a clinical need under Section 503B of the Federal Food, Drug, and Cosmetic Act for pharmacy compounding by outsourcing facilities.

View our other work related to pharmacy compounding.